MX2022000136A - Ligandos del antigeno de membrana especifico de la prostata (psma) y usos de los mismos. - Google Patents
Ligandos del antigeno de membrana especifico de la prostata (psma) y usos de los mismos.Info
- Publication number
- MX2022000136A MX2022000136A MX2022000136A MX2022000136A MX2022000136A MX 2022000136 A MX2022000136 A MX 2022000136A MX 2022000136 A MX2022000136 A MX 2022000136A MX 2022000136 A MX2022000136 A MX 2022000136A MX 2022000136 A MX2022000136 A MX 2022000136A
- Authority
- MX
- Mexico
- Prior art keywords
- psma
- ligands
- specific membrane
- membrane antigen
- prostate specific
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19184015 | 2019-07-02 | ||
| PCT/EP2020/068386 WO2021001360A1 (en) | 2019-07-02 | 2020-06-30 | Prostate specific membrane antigen (psma) ligands and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022000136A true MX2022000136A (es) | 2022-04-27 |
Family
ID=67145647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000136A MX2022000136A (es) | 2019-07-02 | 2020-06-30 | Ligandos del antigeno de membrana especifico de la prostata (psma) y usos de los mismos. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230226227A1 (enExample) |
| EP (1) | EP3993837A1 (enExample) |
| JP (2) | JP7805170B2 (enExample) |
| KR (1) | KR20220044496A (enExample) |
| CN (3) | CN120441497A (enExample) |
| AR (1) | AR119331A1 (enExample) |
| AU (3) | AU2020299974A1 (enExample) |
| BR (1) | BR112021026812A2 (enExample) |
| CA (1) | CA3144557A1 (enExample) |
| CL (1) | CL2021003525A1 (enExample) |
| CO (1) | CO2021017708A2 (enExample) |
| IL (1) | IL289039A (enExample) |
| MX (1) | MX2022000136A (enExample) |
| PH (1) | PH12021553284A1 (enExample) |
| TW (1) | TW202114742A (enExample) |
| WO (1) | WO2021001360A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021219719A1 (en) * | 2020-04-29 | 2021-11-04 | Advanced Accelerator Applications (Italy) Srl | Methods for radiolabelling psma binding ligands and their kits |
| CN121604981A (zh) | 2023-07-21 | 2026-03-03 | 诺华公司 | 靶向psma的放射性配体治疗方案 |
| WO2025125469A1 (en) | 2023-12-13 | 2025-06-19 | Swiss Rockets Ag | Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001271026A1 (en) | 2000-07-11 | 2002-01-21 | Bml, Inc. | Remedies for bone diseases |
| HUE045028T2 (hu) * | 2011-08-05 | 2019-12-30 | Molecular Insight Pharm Inc | Radiojelzett prosztataspecifikus membrán antigén inhibitorok |
| GEP20237479B (en) * | 2013-10-18 | 2023-03-27 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| KR20250057132A (ko) | 2016-03-22 | 2025-04-28 | 더 존스 홉킨스 유니버시티 | 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제 |
| US11478558B2 (en) * | 2017-05-30 | 2022-10-25 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| IL276528B2 (en) * | 2018-02-06 | 2024-11-01 | Univ Johns Hopkins | PSMA Targeted Radiohalogenated Urea-Polyaminocarboxylates For Cancer Radiotherapy |
| WO2020028323A1 (en) * | 2018-07-30 | 2020-02-06 | The Johns Hopkins Universtiy | Competitive prostate-specific membrane antigen (psma) binding agents for the reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy |
-
2020
- 2020-06-30 MX MX2022000136A patent/MX2022000136A/es unknown
- 2020-06-30 JP JP2021578240A patent/JP7805170B2/ja active Active
- 2020-06-30 PH PH1/2021/553284A patent/PH12021553284A1/en unknown
- 2020-06-30 US US17/622,060 patent/US20230226227A1/en active Pending
- 2020-06-30 EP EP20734426.8A patent/EP3993837A1/en active Pending
- 2020-06-30 WO PCT/EP2020/068386 patent/WO2021001360A1/en not_active Ceased
- 2020-06-30 CA CA3144557A patent/CA3144557A1/en active Pending
- 2020-06-30 KR KR1020227003148A patent/KR20220044496A/ko active Pending
- 2020-06-30 AU AU2020299974A patent/AU2020299974A1/en not_active Abandoned
- 2020-06-30 CN CN202510573851.3A patent/CN120441497A/zh active Pending
- 2020-06-30 CN CN202080047295.1A patent/CN114341118A/zh active Pending
- 2020-06-30 CN CN202510573926.8A patent/CN120441498A/zh active Pending
- 2020-06-30 BR BR112021026812A patent/BR112021026812A2/pt unknown
- 2020-07-01 AR ARP200101868A patent/AR119331A1/es unknown
- 2020-07-02 TW TW109122386A patent/TW202114742A/zh unknown
-
2021
- 2021-12-15 IL IL289039A patent/IL289039A/en unknown
- 2021-12-23 CO CONC2021/0017708A patent/CO2021017708A2/es unknown
- 2021-12-28 CL CL2021003525A patent/CL2021003525A1/es unknown
-
2024
- 2024-02-09 AU AU2024200850A patent/AU2024200850B2/en active Active
-
2025
- 2025-07-17 JP JP2025120662A patent/JP2025165975A/ja active Pending
- 2025-11-24 AU AU2025271182A patent/AU2025271182A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021553284A1 (en) | 2022-08-01 |
| JP2025165975A (ja) | 2025-11-05 |
| CO2021017708A2 (es) | 2022-05-20 |
| BR112021026812A2 (pt) | 2022-02-22 |
| CN120441497A (zh) | 2025-08-08 |
| WO2021001360A1 (en) | 2021-01-07 |
| EP3993837A1 (en) | 2022-05-11 |
| JP2022538478A (ja) | 2022-09-02 |
| AU2020299974A1 (en) | 2022-01-27 |
| AR119331A1 (es) | 2021-12-09 |
| TW202114742A (zh) | 2021-04-16 |
| US20230226227A1 (en) | 2023-07-20 |
| AU2024200850A1 (en) | 2024-02-29 |
| CN114341118A (zh) | 2022-04-12 |
| AU2024200850B2 (en) | 2025-09-04 |
| IL289039A (en) | 2022-02-01 |
| CN120441498A (zh) | 2025-08-08 |
| KR20220044496A (ko) | 2022-04-08 |
| AU2025271182A1 (en) | 2025-12-18 |
| CA3144557A1 (en) | 2021-01-07 |
| JP7805170B2 (ja) | 2026-01-23 |
| CL2021003525A1 (es) | 2022-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001662A1 (es) | Compuestos y métodos para la degradación dirigida del receptor de andrógenos | |
| CL2023000630A1 (es) | Anticuerpos anti-ceacam5 y sus conjugados y usos. | |
| MX2020006112A (es) | Complejo que comprende un compuesto orientado a psma vinculado a un radionucleido de plomo o torio. | |
| MX2022000136A (es) | Ligandos del antigeno de membrana especifico de la prostata (psma) y usos de los mismos. | |
| CO2019010943A2 (es) | Anticuerpos de unión a vista a ph ácido | |
| CO2021009053A2 (es) | Inhibidores de apol1 y sus métodos de uso | |
| AR110056A2 (es) | Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos | |
| ECSP099619A (es) | Anticuerpos anti-robo4 y sus usos | |
| CL2017003021A1 (es) | Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos. | |
| PE20210456A1 (es) | Ligandos de psma para la formacion de imagenes y endorradioterapia | |
| PE20191235A1 (es) | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente | |
| CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| MX390931B (es) | Inhibidores marcados con 18f mejorados del antígeno prostático específico de membrana (psma) y su uso como agentes de formación de imágenes para el cáncer de próstata. | |
| AR120883A1 (es) | Anticuerpos anti-fgfr2b | |
| MX2017016681A (es) | Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. | |
| EA202191175A1 (ru) | Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры | |
| PE20200866A1 (es) | Composiciones que contienen conjugados de analogos cannabinoides y metodos de uso | |
| MX2019013071A (es) | Metodo de tratamiento inmunoterapeutico de un tumor. | |
| CO2023002375A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| AR120884A1 (es) | Anticuerpos anti-fgfr2b | |
| MX2022000654A (es) | Sistemas fluorescentes para imagenes biologicas y usos de los mismos. | |
| MX2021014292A (es) | Formulaciones de agentes de imagen de psma. | |
| MX381598B (es) | Combinación farmacéutica que comprende un parvovirus y bevacizumab. | |
| CL2022000894A1 (es) | Moduladores atf6 y sus usos. | |
| MX2019010009A (es) | Composiciones para el cuidado personal. |